VRNA Form 4: RSUs vested and options cashed out at $107 per ADS
Rhea-AI Filing Summary
Verona Pharma plc (VRNA) reporting person Lisa Deschamps, a director, filed a Form 4 disclosing transactions tied to the company's scheme of arrangement with Merck.
At the Effective Time, each ADS, representing eight Ordinary Shares, was paid $107 in cash under the transaction agreement. The filing shows 72,000 Ordinary Shares (equivalent to ADS-based RSUs) were acquired as vested RSU awards and then converted into the cash right to receive ADS consideration. A series of outstanding share options and other equity awards were accelerated and converted into cash payments where the exercise price was below the ADS consideration; multiple option awards totaling 600,000 underlying Ordinary Shares were shown as disposed or converted to cash rights. Following the transactions, the reporting person holds 72,000 Ordinary Shares (direct).
Positive
- RSUs fully vested and converted to cash rights at $107 per ADS, providing immediate value to awardees
- In-the-money options were converted into cash consideration, removing future dilution from those grants
Negative
- Significant equity disposals reported: 84,856 Ordinary Shares disposed as part of the scheme
- Post-transaction direct ownership for the reporting person decreased to 72,000 Ordinary Shares
Insights
Equity awards were accelerated and converted into cash at the deal price; RSUs became vested cash rights.
The Transaction Agreement forced full vesting of time-based RSUs immediately prior to the Effective Time, converting each RSU into the right to receive the ADS consideration of $107 per ADS. That mechanism crystallizes compensation liabilities and simplifies post-close equity settlements.
This treatment affects reported insider holdings and taxable events for recipients; monitor any separate tax withholding disclosures and the timing of cash payments for settlement within the next 30-90 days.
In-the-money options were cashed out, yielding zero post-transaction equity holdings from those grants.
Options with exercise prices below the ADS consideration were converted into cash equal to the excess of $107 per ADS over the exercise price, producing realized cash value for optionholders and removing those option shares from post-close capitalization counts.
Watch for any follow-up disclosures about aggregate cash paid for option conversions and RSU settlements; these figures determine the total cash outflow tied to equity compensation in the transaction.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Restricted Share Unit | 72,000 | $0.00 | -- |
| Disposition | Share Options (Right to Buy) | 200,000 | $0.00 | -- |
| Disposition | Share Options (Right to Buy) | 96,000 | $0.00 | -- |
| Disposition | Share Options (Right to Buy) | 240,000 | $0.00 | -- |
| Disposition | Share Options (Right to Buy) | 64,000 | $0.00 | -- |
| Disposition | Ordinary Shares | 84,856 | $0.00 | -- |
| Exercise | Ordinary Shares | 72,000 | $0.00 | -- |
| Disposition | Ordinary Shares | 72,000 | $0.00 | -- |
Footnotes (1)
- Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer. Represents Ordinary Shares of the Issuer acquired from the Reporting Person by means of a scheme of arrangement (the "Scheme of Arrangement") under Part 26 of the UK Companies Act 2006, pursuant to a transaction agreement, dated as of July 8, 2025 (the "Transaction Agreement"), by and among the Issuer, Merck Sharp & Dohme LLC, a New Jersey limited liability company ("Parent") and Vol Holdings LLC, a Delaware limited liability company and wholly owned subsidiary of Parent ("Bidco"). At the effective time of the Scheme of Arrangement (the "Effective Time"), each holder of the Scheme Shares (as defined in the Scheme of Arrangement) became entitled to receive $13.375 in cash per Scheme Share, without interest and net of any applicable withholding taxes. Because each ADS represents a beneficial ownership interest in eight (8) Ordinary Shares of the Issuer, holders of ADSs as of the Effective Time became entitled to receive eight (8) times the foregoing cash amount, or $107 in cash, without interest and net of any applicable withholding taxes, per ADS (the "ADS Consideration"). Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, each outstanding time-based restricted share unit award ("RSU Award"), unless agreed otherwise, became fully vested, and at the Effective Time, was automatically converted into the right to receive an amount in cash (without interest and subject to all required withholding taxes) equal to the product of (i) the aggregate number of ADSs underlying such RSU Award and (ii) the ADS Consideration. Represents an award of RSUs covering ADSs, which is presented in terms of the equivalent number of Ordinary Shares underlying the ADSs. Each RSU represents a contingent right to receive one (1) ADS of the Issuer. Each ADS represents eight (8) Ordinary Shares of the Issuer. The RSUs have no expiration date. Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, each outstanding share option became fully vested, to the extent unvested, and at the Effective Time, each share option that had an exercise price less than the ADS Consideration was automatically converted into the right to receive an amount in cash equal to the product of (i) the aggregate number of ADSs underlying such share option and (ii) the excess, if any, of (a) an amount equal to the ADS Consideration over (b) the exercise price of such share option.
